Diagnostic Value of the Methylation of Multiple Gene Promoters in Serum in Hepatitis B Virus-Related Hepatocellular Carcinoma

Figure 1

Receiver operating characteristic (ROC) curves analyzing the use of RASSF1A, BVES, and HOXA9 methylation in serum and AFP (≥20 ng/l) for distinguishing hepatocellular carcinoma (HCC) from chronic hepatitis B (CHB). (a) When RASSF1A, BVES, and HOXA9 methylation statuses in serum were utilized together, the AUC was 0.834 (95% CI = 0.774–0.894, ), the sensitivity was 73.5%, and the specificity was 91.1%. (b) When RASSF1A, BVES, and HOXA9 methylation statuses in serum and AFP were combined, the AUC was 0.852 (95% CI = 0.796–0.908, ) and the sensitivity and specificity were 83.7% and 78.9%, respectively.

(a)

(b)